Kidney Transplant Rejection - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Kidney Transplant Rejection - Pipeline Review, H2 2018’, provides an overview of the Kidney Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection

- The report reviews pipeline therapeutics for Kidney Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Kidney Transplant Rejection therapeutics and enlists all their major and minor projects

- The report assesses Kidney Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Kidney Transplant Rejection

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Kidney Transplant Rejection pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Angion Biomedica Corp

Astellas Pharma Inc

Balmes Transplantation SAS

Bioverativ Inc

Catalyst Biosciences Inc

CSL Ltd

Gilead Sciences Inc

Hansa Medical AB

Idogen ...

Amgen Inc

Angion Biomedica Corp

Astellas Pharma Inc

Balmes Transplantation SAS

Bioverativ Inc

Catalyst Biosciences Inc

CSL Ltd

Gilead Sciences Inc

Hansa Medical AB

Idogen AB

ITB-Med AB

Johnson & Johnson

Kyowa Hakko Kirin Co Ltd

Noorik Biopharmaceuticals AG

Novartis AG

Opsona Therapeutics Ltd

Pharmicell Co Ltd

Pharming Group NV

Prolong Pharmaceuticals LLC

Quark Pharmaceuticals Inc

Shire Plc

TolerogenixX GmbH

TxCell SA

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Kidney Transplant Rejection - Overview 6

Kidney Transplant Rejection - Therapeutics Development 7

Kidney Transplant Rejection - Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 5

Kidney Transplant Rejection - Overview 6

Kidney Transplant Rejection - Therapeutics Development 7

Kidney Transplant Rejection - Therapeutics Assessment 16

Kidney Transplant Rejection - Companies Involved in Therapeutics Development 26

Kidney Transplant Rejection - Drug Profiles 37

Kidney Transplant Rejection - Dormant Projects 153

Kidney Transplant Rejection - Discontinued Products 156

Kidney Transplant Rejection - Product Development Milestones 157

Appendix 169

List of Tables

List of Tables

Number of Products under Development for Kidney Transplant Rejection, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Kidney Transplant Rejection, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Kidney Transplant Rejection - Pipeline by Amgen Inc, H2 2018

Kidney Transplant Rejection - Pipeline by Angion Biomedica Corp, H2 2018

Kidney Transplant Rejection - Pipeline by Astellas Pharma Inc, H2 2018

Kidney Transplant Rejection - Pipeline by Balmes Transplantation SAS, H2 2018

Kidney Transplant Rejection - Pipeline by Bioverativ Inc, H2 2018

Kidney Transplant Rejection - Pipeline by Catalyst Biosciences Inc, H2 2018

Kidney Transplant Rejection - Pipeline by CSL Ltd, H2 2018

Kidney Transplant Rejection - Pipeline by Gilead Sciences Inc, H2 2018

Kidney Transplant Rejection - Pipeline by Hansa Medical AB, H2 2018

Kidney Transplant Rejection - Pipeline by Idogen AB, H2 2018

Kidney Transplant Rejection - Pipeline by ITB-Med AB, H2 2018

Kidney Transplant Rejection - Pipeline by Johnson & Johnson, H2 2018

Kidney Transplant Rejection - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018

Kidney Transplant Rejection - Pipeline by Noorik Biopharmaceuticals AG, H2 2018

Kidney Transplant Rejection - Pipeline by Novartis AG, H2 2018

Kidney Transplant Rejection - Pipeline by Opsona Therapeutics Ltd, H2 2018

Kidney Transplant Rejection - Pipeline by Pharmicell Co Ltd, H2 2018

Kidney Transplant Rejection - Pipeline by Pharming Group NV, H2 2018

Kidney Transplant Rejection - Pipeline by Prolong Pharmaceuticals LLC, H2 2018

Kidney Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H2 2018

Kidney Transplant Rejection - Pipeline by Shire Plc, H2 2018

Kidney Transplant Rejection - Pipeline by TolerogenixX GmbH, H2 2018

Kidney Transplant Rejection - Pipeline by TxCell SA, H2 2018

Kidney Transplant Rejection - Dormant Projects, H2 2018

Kidney Transplant Rejection - Dormant Projects, H2 2018 (Contd..1), H2 2018

Kidney Transplant Rejection - Dormant Projects, H2 2018 (Contd..2), H2 2018

Kidney Transplant Rejection - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Kidney Transplant Rejection, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Kidney Transplant Rejection, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports